Antimicrobial Resistance
52. Reynolds R, Antimicrobial resistance in the UK and Ireland, J Antimicrob Chemother, 2009;64(Suppl. 1):i19–23.
53. Allerberger F, Frank A, Gareis R; ABS International, Antibiotic stewardship through the EU project ‘ABS International’, Wien Klin Wochenscher, 2008;120:256–63.
54. Van Gastel E, Costers M, Peetermans WE, et al., Nationwide implementation of antibiotic management teams in Belgian hospitals: a self-reporting survey, J Antimicrob Chemother, 2010;65:576–80.
55. Owens RC Jr, Antimicrobial stewardship: application in the intensive care unit, Infect Dis Clin North Am, 2009;23:683–702.
56. Scaglione F, Minelli EB, De Sarro A, et al., The Charta of Milan: Basic criteria for the appropriate and accurate use of antibiotics: Recommendations of the Italian Society of
Chemotherapy, J Chemother, 2009;21:475–81.
57. Dellitt TH, Owens RC, McGowan JE Jr, et al., Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship, Clin Infect Dis, 2007;44:159–77.
58. Kollef MH, Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front, Clin Infect Dis, 2008;47(Suppl. 1):S3–13.
59. Briceño DF, Quinn JP, Villegas MV, Treatment options for multidrug-resistant nonfermenters, Expert Rev Anti Infect Ther, 2010;8:303–15.
60. Wilcox MH, The tide of antimicrobial resistance and selection, Int J Antimicrob Agents, 2009;34(Suppl. 3):S6–10.
61. Boucher HW, Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication, Clin Infect Dis, 2010;50(Suppl. 1):S4–9.
62. Rice LB, Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria, Cleve Clin J Med, 2007;74(Suppl. 4):S12–20.
63. Bebrone C, Lassaux P, Vercheval L, et al., Current challenges in antimicrobial chemotherapy: focus on beta-lactamase inhibition, Drugs, 2010;70:651–79.
64. Falagas ME, Kastoris AC, Kapaskelis AM, et al., Fosfomycin for the treatment of multidrug-resistant, including extended- spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review, Lancet Infect Dis, 2010;10:43–50.
EUROPEAN INFECTIOUS DISEASE
97
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92